Propylamine

Propylamine

SCHEMBL7725815

CCCN.Oc1cccc2c1CCCC2

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.72
BAD Q92934 1/20 0.72
HTR1A P08908 5/20 0.47
HTR7 P34969 5/20 0.47
HTR1B P28222 2/20 0.47
HTR2A P28223 2/20 0.47
HTR2C P28335 2/20 0.47
ALDH1A1 P00352 2/20 0.47
LMNA P02545 2/20 0.47
HTR6 P50406 1/20 0.47
MEN1 O00255 1/20 0.47
THRA P10827 1/20 0.47
THRB P10828 1/20 0.47
KMT2A Q03164 1/20 0.47
DRD2 P14416 6/20 0.46
DRD3 P35462 6/20 0.46
DRD4 P21917 4/20 0.46
HTR1D P28221 2/20 0.46
DRD1 P21728 1/20 0.46
DRD5 P21918 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29352072 0.85 BCL2L1 (1.00) BCL2L1BADALDH1A1DRD2DRD3
SCHEMBL150894 0.85 BCL2L1 (1.00) BCL2L1BADALDH1A1DRD2DRD3
SCHEMBL1321391 0.83 BCL2L1 (0.68) BCL2L1BADHTR1AHTR7HTR1B
Ammonia Solution, Strong SCHEMBL27679278 0.83 BCL2L1 (0.95) BCL2L1BADALDH1A1DRD2DRD3
SCHEMBL27700160 0.83 BCL2L1 (0.95) BCL2L1BADALDH1A1DRD2DRD3
SCHEMBL150001 0.83 BCL2L1 (0.95) BCL2L1BADALDH1A1DRD2DRD3
SCHEMBL152396 0.83 BCL2L1 (0.95) BCL2L1BADALDH1A1DRD2DRD3
SCHEMBL29442708 0.81 BCL2L1 (0.91) BCL2L1BADHTR1AHTR7HTR1B
SCHEMBL154077 0.81 BCL2L1 (0.91) BCL2L1BADHTR1AHTR7HTR1B
Ethyl Acetate SCHEMBL27490737 0.76 BCL2L1 (0.62) BCL2L1BADALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160015684-A1 COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS SPRIASO LLC 2016-01-21 US claimed
US-6372920-B1 ALKYLATING 2-AMINOTETRALIN IN PRESENCE OF BASE SELECTED FROM ALKALI METAL CARBONATES AND BICARBONATES, WHEREIN AMOUNT OF BASE IS LESS THAN ABOUT 1.9-FOLD MOLAR EXCESS WITH RESPECT TO AMOUNT OF 2-AMINOTETRALIN ADERIS PHARMACEUTICALS, INC. 2002-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015684-A1 COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS SLC7A1, CYP2D6, CYP3A7 BCL2L1 2906/4885BAD 4050/4885HTR1A 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.